Too Little Too Late: Effect of Poor Access to Biologics for Patients with Rheumatoid Arthritis

REFERENCES

1. 1.↵
   1. Pincus T,
   2. Sokka T,
   3. Kautiainen H

   . Patients seen for standard rheumatoid arthritis care have significantly better articular, radiographic, laboratory, and functional status in 2000 than in 1985. Arthritis Rheum 2005;52:1009–19.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Mertelsmann-Voss C,
   2. Lyman S,
   3. Pan TJ,
   4. Goodman SM,
   5. Figgie MP,
   6. Mandl LA

   . US trends in rates of arthroplasty for inflammatory arthritis including rheumatoid arthritis, juvenile idiopathic arthritis, and spondyloarthritis. Arthritis Rheumatol 2014;66:1432–9.

   OpenUrl
3. 3.↵
   1. Harty L,
   2. O’Toole G,
   3. FitzGerald O

   . Profound reduction in hospital admissions and musculoskeletal surgical procedures for rheumatoid arthritis with concurrent changes in clinical practice (1995–2010). Rheumatol 2014;54:666–71.

   OpenUrl
4. 4.↵
   1. Hekmat K,
   2. Jacobsson L,
   3. Nilsson J-Å,
   4. Petersson IF,
   5. Robertsson O,
   6. Garellick G,
   7. et al.

   Decrease in the incidence of total hip arthroplasties in patients with rheumatoid arthritis—results from a well defined population in south Sweden. Arthritis Res Ther 2011;13:R67.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Stamp LK,
   2. Haslett J,
   3. Chapman P,
   4. O’Donnell J,
   5. Raja R,
   6. Rothwell A,
   7. et al.

   Rates of joint replacement surgery in New Zealand, 1999–2015: a comparison of rheumatoid arthritis and osteoarthritis. J Rheumatol 2017;44:1823–7.

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   1. Johnson BK,
   2. Goodman SM,
   3. Alexiades MM,
   4. Figgie MP,
   5. Demmer RT,
   6. Mandl LA

   . Patterns and associated risk of perioperative use of anti-tumor necrosis factor in patients with rheumatoid arthritis undergoing total knee replacement. J Rheumatol 2013;40:617–23.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   1. Goodman SM,
   2. Ramsden-Stein DN,
   3. Huang WT,
   4. Zhu R,
   5. Figgie MP,
   6. Alexiades MM,
   7. et al.

   Patients with rheumatoid arthritis are more likely to have pain and poor function after total hip replacements than patients with osteoarthritis. J Rheumatol 2014;41:1774–80.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   1. Hockley T,
   2. Costa-Font J

   . A common disease with uncommon treatment: European guideline variations and access to innovative therapies for rheumatoid arthritis. 2012. [Internet. Accessed October 10, 2017.] Available from: https://policy-centre.com/wp-content/uploads/2017/04/RAGuidelines.pdf
9. 9.↵
   1. Kalkan A,
   2. Hallert E,
   3. Bernfort L,
   4. Husberg M,
   5. Carlsson P

   . Costs of rheumatoid arthritis during the period 1990–2010: A register-based cost-of-illness study in Sweden. Rheumatol 2014;53:153–60.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Birnbaum H,
    2. Pike C,
    3. Kaufman R,
    4. Marynchenko M,
    5. Kidolezi Y,
    6. Cifaldi M

    . Societal cost of rheumatoid arthritis patients in the US. Curr Med Res Opin 2010;26:77–90.

    OpenUrlCrossRefPubMed
11. 11.↵
    1. UK National Audit Office

    . Services for people with rheumatoid arthritis. 2009. [Internet. Accessed October 10, 2017.] Available from: www.nao.org.uk/report/services-for-people-with-rheumatoid-arthritis/
12. 12.↵
    1. Lekander I,
    2. Borgström F,
    3. Lysholm J,
    4. van Vollenhoven RF,
    5. Lindblad S,
    6. Geborek P,
    7. et al.

    The cost-effectiveness of TNF-inhibitors for the treatment of rheumatoid arthritis in Swedish clinical practice. Eur J Health Econ 2013;14:863–73.

    OpenUrlCrossRefPubMed
13. 13.↵
    1. Cross M,
    2. Smith E,
    3. Hoy D,
    4. Carmona L,
    5. Wolfe F,
    6. Vos T,
    7. et al.

    The global burden of rheumatoid arthritis: estimates from the Global Burden of Disease 2010 study. Ann Rheum Dis 2014;73:1316–22.

    OpenUrlAbstract/FREE Full Text
14. 14.↵
    1. Dörner T,
    2. Strand V,
    3. Castañeda-Hernández G,
    4. Ferraccioli G,
    5. Isaacs JD,
    6. Kvien TK,
    7. et al.

    The role of biosimilars in the treatment of rheumatic diseases. Ann Rheum Dis 2013;72:322–8.

    OpenUrlAbstract/FREE Full Text